Summer Medical Student Respiratory Research Fellowship

Raouf Amin, MD

Dr. Amin’s research program focuses on 3 areas of investigations in pediatric sleep including upper airway function in children with sleep apnea, mechanisms of resolution of sleep apnea after surgical interventions such as adenotonsillectomy and bariatric surgeries, and the cardiovascular and neurocognitive outcomes of sleep apnea in children. Medical students will receive specific training in the methods of hypothesis-driven clinical research. Students will also be exposed to other sleep research projects and receive mentorship on abstract preparation and will be invited to collaborate on manuscripts, as appropriate.

Kavisha Arora, PhD

Dr. Arora’s research involves developing personalized medicine in Cystic Fibrosis (CF) based on stem cell-derived epithelial culture models and identifying signaling pathways relevant to mucociliary clearance defects in the lung. Her current research projects include understanding the role of autophagy in the regulation of ciliary function and resolution of bacterial infection in the airways.

Tom Boat, MD

Dr. Boat is a pediatric pulmonologist and former Chair of Pediatrics at Cincinnati Children’s and Dean of the University of Cincinnati College of Medicine. Dr. Boat oversees the CF WELL, which is a program that is focused to fostering family wellness and enhancing health outcomes for both patients with disabling or life-threatening chronic diseases and their families. Program components have targeted improved sleep, more family focused exercise, better nutrition, a higher level of school success for chronic disorder-disadvantaged children, and ability of the family to better manage stress that is a part of living with chronic disease. Research projects span a spectrum from assessing needs of families in their quest to improve wellness, a better quality of life, and meet the care needs of their child with extraordinary health care needs; to designing and implementing interventions that can be tested using an array of clinical research designs, and if beneficial inserted into the chronic care model. Extension of learnings with families of children with CF in Cincinnati will be shared with other CF Centers and extended to other chronic disease care programs, starting with those at Cincinnati Children's. Research projects in progress or planning that offer SMURFF awardees opportunities to engage a research project include:

1. Ascertaining the extent and nature of sleep insufficiency in families of children with CF, led by Dr Barbara Chini, and piloting an intervention designed to improve sleep by sleep psychologist, Dr. 
   Kelly Byars.
2. Working with Dr. Stephanie Filigno and Ms. Sarah Strong on the assessment of challenges presented by school for CF children and families, and identifying their risk factors for academic success.
3. Ascertaining the relationships among nutrition, exercise, weight gain, body composition, muscle strength and pulmonary function for patients with CF, working with CF team experts in exercise physiology and nutrition.
4. Working with Dr. Chris Siracusa and the pulmonary function technicians to assess the impact of several potential mind-body interventions on stress reduction interventions at the time of pulmonary function testing, a situation that is identified by one third of CF patients as a source of anxiety and considerable stress.
5. Other research opportunities will undoubtedly emerge as the CF WELL program advances its initiatives.

Michael Borchers, PhD

Dr. Borcher’s research focuses on immune function in chronic pulmonary diseases. His laboratory studies the role of natural killer cells, T cells, dendritic cells and macrophage in in chronic obstructive pulmonary disease focusing on the response to viral and bacterial exacerbations. In addition, he studies immune function in neonates examining the response to RSV in the context of second hand smoke exposure.

John Brewington, MD

Dr. Brewington is a pediatric pulmonologist who focuses primarily on epithelial biology in cystic fibrosis (CF). His research aims to maximize the individual benefit from “modulator” drugs, a relatively new group of treatments that directly improve the dysfunctional protein that causes CF. These drugs are only available for certain subgroups of patients, based on their specific genotype, and the largest group receives the smallest benefits. To improve this benefit, there is ongoing work to understand the negative interactions between these modulators and classical CF therapies (such as inhaled beta-agonists). Additionally, the lab is working on generation of patient-derived, individualized model systems to predict who will benefit from these new drugs, and to potentially expand them to new genotypes. A variety of techniques are used in these studies, with a focus on cell-culture models and assays (both traditional and novel) of ion/fluid transport.

James Bridges, PhD

Dr. Bridges investigates the role of hypoxia inducible factors (HIFs) and downstream gene targets in chronic lung disease. These goals are achieved by utilizing both gain and loss-of-function mouse models to evaluate the mechanistic basis underlying the pathophysiologic changes in pulmonary function associated with altered HIF activity.

J.P Clancy, MD

Dr. Clancy’s laboratory and clinical research projects focus primarily on airway epithelial biology, examining restorative strategies to treat cystic fibrosis and to restore protease dysregulation in lung inflammatory disorders. The goals of his research program are 1) to examine strategies to restore activity to mutant, disease-causing CFTR mutations in preclinical model systems and in human subjects, 2) to develop new biomarkers of CFTR activity, and 3) to investigate novel inflammatory pathways contributing to lung injury in acute and chronic pulmonary diseases. Dr. Clancy utilizes these themes to provide research training platforms to future physician-scientists, focusing on translational research across model systems to human subjects.

Zack Cleveland, PhD

Dr. Cleveland’s research interest is centered on developing magnetic resonance-based imaging techniques to visualize lung structure and function in humans and in small animal models of disease and injury. A particular focus of his research has been on visualizing ventilation and diffusive gas uptake using hyperpolarized (HP) 129Xe MRI. His focus will be to develop novel magnetic resonance imaging methods to assess regional lung function in preclinical animal models, as well as adult and pediatric populations. His emphasis will be directed toward developing techniques to quantitatively image pathophysiology in poorly understood disorders such as acute lung injury (ALI) and idiopathic pulmonary fibrosis.

Patricia C. Fulkerson, MD, PhD

Dr. Fulkerson’s research program is focused on the biology of the eosinophil lineage-committed progenitor (EoP). The overall aim is to identify novel therapeutic targets to block eosinophil production for the treatment of patients with eosinophilic disorders such as allergic asthma. Tissue eosinophilia is primarily attributed to the influx of mature eosinophils from the circulation, but recent studies suggest that another mechanism may also be at work. EoPs have been identified in increased numbers within allergic mucosa and in sputum from patients with asthma, suggesting eosinophil differentiation in situ may contribute to the accumulation of effector eosinophils in tissues. Potential projects for medical students working in the lab include investigating the contribution of EoPs mobilized from the bone marrow during an allergic response to eosinophil accumulation in the asthmatic lung using experimental models of asthma and innovative culture systems we have developed in the lab.

Daniel Grossoehme, DMin

Dr. Grossoehme’s lab conducts discovery-oriented behavioral/social science of psychological and spiritual factors contributing to treatment adherence, and develops and tests interventions to enhance disease self-management, coping and health-related quality of life. Medical students will share in the on-going efforts of the lab: recruiting participants, conducting Daily Phone Diary interviews, assisting with data entry, and analyzing social network data. They may conduct qualitative interviews, or serve as interventionists in a behavioral trial, depending on timing and interests. Students will receive regular mentoring to successfully complete their project—whether in cystic fibrosis or another pulmonary population--and present their findings by poster and or manuscript.

Theresa Guilbert, MD

Dr. Guilbert is a pediatric pulmonologist performing clinical research focusing on identifying the roles of early life risk factors, exposures, and environment interactions that lead to early childhood asthma and recurrent wheezing. Much of Dr. Guilbert’s research experience has been with multicenter trials and networks. Another area of research interest is using clinical electronic medical data and subsequent linking of this data to public and databases on environmental, socioeconomic, and demographic profiles in order to identify asthma phenotypes. Specific interventions will be targeted to these phenotype populations and clinical outcomes will then be followed in the electronic medical record. Dr. Guilbert utilizes these research interests to provide research training opportunities for future physician-scientists.

William Hardie, MD

Dr. Hardie’s laboratory is primarily focused on examining cell signaling pathways that lead to pulmonary fibrosis and to determine whether pharmacological inhibitors currently in clinical trials are effective in reversing fibrosis or preventing progression. The goal is to generate preclinical data, which may be used to support clinical trials in disorders causing pulmonary fibrosis. Medial students working in the laboratory will participate in both in vivo animal models as well as cell-based model systems testing interventions to prevent or reverse progressing fibrosis. Students will be carefully mentored to develop a hypothesis-driven project and trained in the methodologies needed to address the questions.

Gurjit (Neeru) Hershey MD, PhD

Dr. Hershey’s research centers on identifying the genes and environmental factors important in promoting asthma and allergy, especially at the epithelial surfaces, and dissecting the molecular mechanisms underlying their contributions. Current projects in the laboratory include:  (1) Elucidation of epithelial genes and exposures critical to allergic disease; (2) Genomic biomarkers of treatment response in childhood asthma; (3) Gene: environment interactions in asthma and allergic diseases; (4) Mechanistic basis of the adverse effect of traffic pollution exposure in early life; (5) pathogenesis of atopic dermatitis; and (6) Identification of genetic and biologic markers of allergic diseases.

Tanya Kalin, MD, PhD

Dr. Kalin’s laboratory focuses on the transcriptional regulation of carcinogenesis. We use mouse cancer models to gain insight into regulation of cell signaling pathways required for tumor initiation, progression, metastasis and tumor angiogenesis. The ultimate goal of our research program is to identify novel target genes for diagnosis, prevention and treatment of lung and prostate cancers.

Vladimir Kalinichenko, MD, PhD

Dr. Kalinichenko is interested in transcriptional regulation of epithelial, endothelial and inflammatory cells during lung development and lung injury. The focus is made to Winged helix/Forkhead Box (Fox) proteins FoxM1, FoxF1 and FoxF2 and their role in regulating cell signaling pathways required for cellular proliferation, differentiation, motility and survival, ultimately identifying novel mechanisms that cause human lung malformations and promote lung repair after the injury. Our research led to identification of mutations in FoxF1 gene locus in 30% of patients with Alveolar Capillary Dysplasiawith Misalignment of Pulmonary Veins (ACD/MPV), a developmental disorder with mortality rate of 100% during first several month of life. Currently, we are using various transgenic and knockout mouse models to determine the role of Fox proteins in lung development and various lung diseases, such as ACD, Bronchopulmonary dysplasia (BPD), asthma and lung cancer.

Paul Kingma MD, PhD

Dr. Kingma is a neonatologist and Co-Director of the Fetal Care Center of Cincinnati. His clinical expertise in neonatology includes managing children with congenital diaphragmatic hernias and neonatal infections. Dr. Kingma’s lab investigates the role of the innate immune system in pulmonary infections in children. Specific projects currently focus on the role of surfactant protein D in neonatal sepsis and acute respiratory distress syndrome and on lung injury in congenital diaphragmatic hernia patients. Students will work directly with Dr. Kingma and his associates on any of these projects during their summer tenure.

Elizabeth Kramer, MD, PhD

Dr. Kramer is a pediatric pulmonologist interested in genetic modifiers of cystic fibrosis (CF) related lung disease. Her overall aim is to identify novel therapeutic targets in CF. One of the best studied CF lung disease modifiers and biomarkers is transforming growth factor beta (TGF-β), a cytokine that drives CF related pulmonary abnormalities including epithelial ion channel dysregulation, goblet cell hyperplasia, and inflammation. Her research focuses on the impact of TGF-β on CF mice and patient-derived CF airway cell models, with a focus on the unique susceptibility of CF models to the detrimental effects of TGF-β.

Ian Lewkowich, PhD

Dr. Lewkowich’s laboratory is focused on the immunologic mechanisms responsible for the development of severe allergic asthma. Using a mouse model of allergic asthma in which one strain develops a phenotype characteristic of mild asthma and others develop a phenotype characteristic of severe disease, his group has identified several novel mechanisms through which asthma severity is regulated. Utilizing these mouse models his group is specifically investigating the role of T-cell regulatory immune cells and dendritic cells which influence the inflammatory response to asthmagenic antigens. Students would have the opportunity to work directly using these experimental models of asthma developed in the laboratory.

Satish Madala PhD

Dr. Madala’s research interests are to identify the cellular and molecular mechanisms involved the initiation, maintenance, and progression of pulmonary fibrosis. His lab’s research tools include using molecular, biochemical and immunology methods to identify novel therapeutic targets in chronic lung diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), and cystic fibrosis (CF). The lab’s early studies using several mouse models of fibrosis have revealed that multiple growth factors contribute to the deposition of collagen and other extracellular matrix (ECM) proteins in the lung. The lab’s recent studies have helped to define unique functions of fibrocytes and their heterogeneous interactions with other lung stromal cells in causing the expansion of adventitial and pleural fibrotic lesions in the lung.

Cormac McCarthy, MD, PhD

Dr. McCarthy’s research interests include rare lung disease, including alpha 1 antitrypsin deficiency, cystic fibrosis, pulmonary alveolar proteinosis and lymphangioleiomyomatosis. Specific translational research is focused on pulmonary alveolar proteinosis and the role of cholesterol homeostasis in alveolar macrophage function. These projects include investigating the role of cholesterol in the pathogenesis of surfactant lung diseases and identifying therapeutic targets, investigating the phenotype of alveolar macrophages by RNAseq analysis, the interaction between Nocardia and macrophage. Dr. McCarthy’s group is also involved in conducting a clinical trial of pioglitazone in humans, as a therapy to target cholesterol homeostasis in pulmonary alveolar proteinosis

Frank McCormack, MD

Dr. McCormack is Division Director for adult pulmonary critical care and sleep medicine at the University of Cincinnati. His basic laboratory focus includes examining the pathogenesis of lung disorders including pulmonary Langerhan's cell histiocytosis, pulmonary alveolar microlithiasis, and pulmonary lymphangioleiomyomatosis, rare diseases affecting both children and adults. He is also interested in the role of the pulmonary epithelium in innate immunity, especially as it relates to influenza. In the clinical research realm, he has an active trial program in rare lung diseases.

Louis Muglia, MD, PhD

Dr. Muglia has pioneered the in vivo analyses of regulation of the endocrine stress response and the molecular pathways leading to birth using novel genetically altered mutant mice. These studies have evolved over the last decade to specifically focus on the mechanisms controlling the timing for birth in humans using genetics and comparative genomics. The composition of the biological clock metering the duration of human gestation remains a central question in reproductive biology. The goal of the Muglia laboratory is to understand the molecular timing machinery comprising this biological clock to prevent or better treat human preterm labor.

A.P. Naren, PhD

Dr. Naren's laboratory studies interactions between the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein and its binding partners and defining how spatiotemporal regulation of CFTR-containing macromolecular complexes in the apical compartment of polarized epithelial cells lining the secretory epithelia regulates overall fluid secretion. The long-term goal of this work is to identify new drug targets for cystic fibrosis and other diseases resulting from CFTR dysfunction and provide insights into the etiology of diseases associated with CFTR-interacting molecules.

Anne-Karina Perl, PhD

Dr. Perl lab utilizes conditional transgenic mice to learn about lung development and to study lung regeneration, and more recently, to study aberrant epithelial repair and lung fibrosis. The Perl lab is integrating lessons learned from lung development with lung repair and successfully established novel conditional mouse models to study re-alveolarization and bronchiolar repair after acute and chronic injury. Current research projects are focused toward understanding the cellular and molecular mechanisms related to the cure of lung diseases including bronchopulmonary dysplasia, emphysema, chronic obstructive pulmonary disease (COPD) and bronchiolitis obliterans.

Marc Rothenberg MD, PhD

Dr. Rothenberg’s lab has several areas of concentration. The main objective is to elucidate the processes involved in allergic responses in the gastrointestinal tract and lung using cutting-edge approaches of molecular biology, genetics, biochemistry, translational medicine, and computer computation. The importance of key molecules in the body that perpetuate the allergic responses by examination of genetically induced experimental mouse models are employed. Dr. Rothenberg’s lab characterizes the regulation and pathways responsible for eosinophil development and activation and tests the importance and dysfunction of these pathways in patients with inflammatory diseases such as eosinophilic esophagitis and hypereosinophilic syndromes. A direct clinical project includes identifying genetic variations that may predispose patients to eosinophilic disorders.

Patrick H. Ryan, PhD, MS

Dr. Ryan is an environmental epidemiologist whose research interests include air pollution epidemiology and exposure assessment. Currently he is the principal investigator of the Cincinnati Childhood Allergy and Air Pollution Study (CCAAPS), a longitudinal birth cohort study of the effects of diesel exhaust particles on children’s respiratory health and neurodevelopment. His research with the CCAAPS study includes the development of land-use regression models for air pollution exposure assessment and the association between air pollution, respiratory health, and neurobehavioral development. His research also includes the application of novel sensor technology for personal sampling of air pollution, the effectiveness of anti-idling efforts to reduce air pollution exposures at schools, and the use of HEPA filtration to reduce indoor air pollution exposure.

Grant Schulert, MD, PhD

The long-term goal of the Schulert Lab is to understand the pathogenesis of severe inflammatory disorders of childhood, and in particular systemic juvenile idiopathic arthritis (systemic JIA). Although systemic JIA is considered a subtype of JIA, it has distinct characteristics, notably prominent systemic features such as prolonged spiking fevers, rash, lymphadenopathy and serositis. Recently, a severe inflammatory chronic lung disease has been identified in a subset of children with systemic JIA. The nature and pathogenesis of this lung disease is unclear, but it is associated with a persistent disease course and high mortality. Current work in the Schulert Lab focuses on innate immune effectors in systemic JIA, clinical and laboratory features of systemic JIA-associated lung disease, and genetic factors that influence disease course.

Samir S. Shah, MD, MSCE

Shah is a pediatric infectious diseases and pediatric hospital medicine physician whose research focuses on improving the efficiency and quality of care of children hospitalized with common, serious infections such as pneumonia and asthma. Ongoing projects include studying the comparative effectiveness of different antibiotics in the treatment of community-acquired pneumonia and developing novel databases to conduct comparative effectiveness research in asthma.

Narong Simakajornboon MD

Dr. Simakajornboon researches the correlation between periodic limb movement disorder (PLMD) in children and low iron storage in a larger patient population. The effect of iron therapy on PLMD is prospectively investigated in a double blinded, placebo-controlled approach. All pediatric patients with PLMD at Cincinnati Children's are being recruited into the study. An overnight polysomnographic evaluation is performed in all patients to confirm the presence and severity of disease. Complete blood count, serum levels of iron, total iron-binding capacity, percentage iron saturation and ferritin is obtained in all patients and compared with age and sex-matched control. Patients with low iron storage are randomly assigned to receive treatment with either iron sulfate or placebo. The treatment response will be measured by an improvement in clinical symptoms, actigraphy monitoring and overnight polysomnographic study. Medical students will participate in the recruitment and data analysis of this ongoing project.

Rhonda Szczesniak, PhD

Dr. Szczesniak is a statistician who specializes in the clinical translation of dynamic prediction models for child health and care. Her developments have included flexible nonlinear analyses for ambulatory blood pressure monitoring, glucose monitoring and lung function monitoring. Her current work focuses on cystic fibrosis research, specifically on developing forecasting models of rapid lung function decline, to be used for personalized medicine. She has mentored students in biostatistics and pulmonary medicine, and teaches longitudinal data analysis to students on the UC campus.

Joanna Thomson, MD 

Dr. Thomson is a pediatric hospitalist whose research focuses on the hospital management of acute respiratory infections in children with neurologic impairment. Her current work seeks to identify hospital management practices associated with better outcomes in this population through comparative effectiveness research with an eventual goal to develop and implement care recommendations.

Chris Towe, MD

Dr. Towe’s research focus is improving outcomes for pediatric patients with rare lung diseases, lung injury secondary to immunologic insults and lung transplants. This is accomplished by understanding all aspects of these rare lung diseases including: pathogenesis, early detection, diagnosis, prevention, management and treatment. One primary disease of interest is bronchiolitis obliterans, a non-reversible and frequently progressive lung disease that occurs idiopathically, post-viral infection, post-bone marrow transplant and post-lung transplant. Medical students will get exposure to both clinical and translational research efforts with collaborators in pulmonary biology, pulmonary imaging, radiology, pathology, rheumatology, bone marrow transplant and lung transplant.

Bruce Trapnell MD

Dr. Trapnell has a longstanding interest and effort in translational pulmonary research focused to molecular pathogenesis, diagnosis, and therapeutic development for rare lung diseases including cystic fibrosis, pulmonary alveolar proteinosis, alpha 1 antitrypsin deficiency, lymphangioleiomyomatosis and pediatric interstitial lung diseases. Dr. Trapnell’s basic, clinical, and translational research in animals and humans uses biochemical, physiologic, genetic, bioinformatics and clinical trial approaches.

Brian Varisco MD

Dr. Varisco is in Critical Care Medicine and his laboratory focuses on understanding the role of stretch in regulating postnatal lung morphogenesis. Specific areas of focus are the role of stretch in the transcriptional and non-transcriptional regulation of lung matrix remodeling, the role of matrix remodeling in inducing microvascular expansion, and defining how lung stretch influences epithelial and mesenchymal signaling pathways. The ultimate goal of the Varisco laboratory is to understand how the postnatal lung grows in a ventilation-perfusion matched manner and to leverage this knowledge to develop novel therapies to improve lung health in patients with congenital and acquired disorders of alveolar simplification.

Jeff Whitsett MD

Dr. Whitsett leads a well-established laboratory that has focused its attention to the elucidation of cellular and molecular mechanisms regulating lung formation and function.  The laboratory has a long-standing interest in the roles of surfactant proteins SP-A, SP-B, SP-C, SP-D, and GM-CSF in innate host defense and pulmonary function.  The mechanisms controlling lung epithelial specific gene transcription are an active area of study, seeking to determine the functions of a number of transcription factors, including the members of the NKX, FOX, SOX, GATA, and ETS families of transcription factors that regulate lung cell differentiation.  Genetic pathways mediating lung morphogenesis, maturation, and repair are actively studied, seeking to determine the roles of cell signaling and gene transcription in the pathogenesis of lung disease.  The studies seek to understand the molecular pathways causing chronic lung diseases including asthma, cystic fibrosis, emphysema, and lung cancer.  The laboratory makes extensive use of conditional, lung specific gene targeting in transgenic mice.  Systems biology, with an emphasis on bioinformatics of genomic and expression data, are applied to the study of lung biology.  In vivo and in vitro studies are designed to elucidate the cellular and molecular processes regulating lung function.  There are many opportunities for the study of both established and novel pathways critical for lung formation and disease pathogenesis within the laboratory.

Kathryn Wikenheiser-Brokamp MD, PhD

Dr. Wikenheiser-Brokamp is a clinical pathologist with research programs in lung development and cancer. Her laboratory studies the genetic and developmental basis of lung disease, with specific interest in the molecular mechanisms controlling epithelial cell growth, differentiation and signaling.  Dr. Wikenheiser-Brokamp is specifically interested in mechanisms underlying retinoblastoma (Rb), p16 and p53 tumor suppressor control of epithelial progenitor/stem cell growth and lung carcinogenesis. She also studies the role of Dicer1, and the miRNAs it generates, in lung disease. With mentorship by Dr. Wikenheiser-Brokamp and other laboratory members, the students design controlled experiments, organize and interpret data, and present their findings in oral and/or poster format at laboratory meetings and institutional symposia.

Jason Woods, PhD

Dr. Woods is one of the world’s leading experts on hyperpolarized-gas MRI and the use of such gas MRI to measure regional lung function, microstructure and physiology. Dr. Woods directs the Center for Pulmonary Imaging Research—a multidisciplinary research and training program between Pulmonary Medicine and Radiology. His current ongoing research projects include development of MR-imaging biomarkers to quantify i) alveolar size and morphometry during development and as a result of premature birth, ii) efficacy of treatment after regional or endobronchial interventions, iii) imaging after lung transplantation, and iv) the use of murine models of disease, all ultimately to perform longitudinal monitoring without ionizing radiation in pediatric patients. Possible student projects include studies related to murine lung transplantation, morphometric validation of in-vivo MRI, and quantitative image analysis.

Tesfaye B. Mersha, PhD

Dr. Mersha's research combines quantitative, ancestry and statistical genomics approaches to unravel genetic and non-genetic contributions to complex diseases and racial disparities in human population, particularly asthma and asthma-related allergic disorders. Current research in his laboratory include: 1) admixture and association analysis; 2) transcriptome profiling studies; 3) microbiome/epigenome analysis among allergic immigrants, and 4) developing web-based bioinformatics tools specifically designed to integrate omics resources from public databases (e.g., 1000 Genomes Project, ENCODE and Epigenome Roadmap). Dr. Mersha's long-term career goals are to develop a program that will lead to an in-depth understanding of the complex interplay between genomic variations and environmental exposure risk factors in the etiology of complex diseases, including asthma.

Assem Ziady, PhD

The Ziady laboratory focuses on the differential regulation of Nrf2 signaling pathways in the inflammatory lung disease observed cystic fibrosis (CF). The lab has unique expertise in developing and characterizing DNA nanoparticles for nonviral gene delivery to the lung, liver, and brain. In addition, the lab has extensive experience with proteomic analyses for biomarker discovery and the examination of systems biology of various tissues. Potential summer student projects include: 1) Analyzing the database of serum protein differences in mild versus severe lung disease in cystic fibrosis. 2) Examination of how gene transfer enhancing compounds impact the cellular distribution of gene delivery in the lung. 3) Examining the impact of CFTR modulators on inflammatory signaling by primary airway epithelial cells and serum biomarkers of progression of pulmonary fibrosis.